Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
By J. Saurat, G. Stingl, Louis Dubertret, K. Papp, R. Langley, J. Ortonne, K. Unnebrink, M. Kaul, A. Camez. British Journal of Dermatology, 2007
720 citations recorded by the source corpus.
Subfields: Immunology, Rheumatology
View Paper: https://www.semanticscholar.org/paper/eb34bcf7892ca77e92a9b33e690b57faf8dcbc7c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- U. Mrowietz
- K. Kragballe
- P. Spuls
- C. Griffiths
- P. Gisondi
- K. Reich
- L. Iversen
- L. Kemény
Citations in the corpus
- Definition of treatment goals for moderate to severe psoriasis: a European consensus (2010, background): “On the other hand, methotrexate or fumarates have a slower onset of action, and the maximum therapeutic response may only be achieved after several months of treatment [19, 21].”